News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
225,954 Results
Type
Article (12983)
Company Profile (22)
Press Release (212949)
Section
Business (71084)
Career Advice (1103)
Deals (14387)
Drug Delivery (34)
Drug Development (34365)
Employer Resources (46)
FDA (6541)
Job Trends (5759)
News (124701)
Policy (10296)
Tag
Academia (753)
Africa (315)
Alliances (10944)
Alzheimer's disease (423)
Antibody-drug conjugate (ADC) (27)
Approvals (6527)
Arizona (39)
Asia (14739)
Australia (2241)
Bankruptcy (106)
Best Places to Work (4708)
Biosimilars (30)
Breast cancer (45)
C2C Services and Suppliers (21972)
California (925)
Canada (471)
Cancer (350)
Career advice (874)
Cell therapy (56)
China (84)
Clinical research (28274)
Collaboration (79)
Colorado (39)
Compensation (31)
Connecticut (59)
COVID-19 (955)
Data (317)
Delaware (33)
Diabetes (47)
Diagnostics (2066)
Drug pricing (26)
Earnings (48324)
Employer resources (42)
Europe (32447)
Events (31006)
Executive appointments (57)
FDA (6690)
Florida (118)
Funding (81)
Gene therapy (36)
GLP-1 (304)
Government (1487)
Healthcare (6719)
Hotbed/Location (152458)
Illinois (86)
Indiana (75)
Infectious disease (970)
Inflammatory bowel disease (37)
Interviews (193)
IPO (8305)
Job creations (1171)
Job search strategy (767)
Kansas (36)
Layoffs (134)
Legal (2062)
Liver cancer (30)
Lung cancer (79)
Maine (31)
Manufacturing (47)
Maryland (165)
Massachusetts (646)
Medical device (4740)
Medtech (4742)
Mergers & acquisitions (6096)
Metabolic disorders (159)
Michigan (37)
Minnesota (57)
Neuroscience (510)
New Jersey (283)
New York (325)
NextGen Class of 2024 (2058)
Non-profit (1519)
North Carolina (215)
Northern California (423)
Obesity (101)
Ohio (34)
Opinion (59)
Patents (25)
Pennsylvania (269)
People (7823)
Phase I (7449)
Phase II (12197)
Phase III (10929)
Pipeline (118)
Postmarket research (1207)
Preclinical (2457)
Radiopharmaceuticals (88)
Rare diseases (61)
Real estate (1314)
Regulatory (7178)
Research institute (768)
Resumes & cover letters (206)
South America (463)
Southern California (383)
Startups (1130)
Texas (121)
United States (3809)
Vaccines (232)
Washington State (120)
Weight loss (85)
Date
Last 7 days (376)
Last 30 days (1395)
Last 365 days (16097)
2024 (12137)
2023 (16184)
2022 (20646)
2021 (20272)
2020 (19030)
2019 (16793)
2018 (12749)
2017 (11971)
2016 (10566)
2015 (12716)
2014 (9228)
2013 (7262)
2012 (7941)
2011 (8061)
2010 (7267)
225,954 Results for "5".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pharm Country
JOGO Health Closes $5.5M in Round Led by Hourglass Ventures, Extends Investment Opportunity for Public to Invest Alongside Mayo Clinic Ventures
JOGO Health, a medtech company treating chronic pain and neuromuscular disorders, announced it has closed over $5.5 million in an investment round led by Hourglass Ventures.
June 18, 2024
·
2 min read
Genetown
Insulet Announces Omnipod 5 Launch in France and U.S. Innovation Updates
Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod® brand of products, made several exciting announcements regarding the Omnipod 5 Automated Insulin Delivery System, including its availability in France with Dexcom G6 compatibility, as well as two updates for the U.S. market — the commencement of the Omnipod 5 with Dexcom G7 integration full commercial launch as well as the limited market release of the Omnipod 5 App for iPhone.
June 20, 2024
·
5 min read
Press Releases
BriaCell Therapeutics Announces $5 Million Offering
October 1, 2024
·
4 min read
GPRC5D Targeted Drugs Clinical Trial Market Opportunity Insight
G-protein coupled receptor family C group 5 member D, or GPRC5D, has come up as a protein being considered for the development of therapeutic interventions in cancer
May 24, 2024
·
2 min read
KFSHRC Performs Over 5,000 Successful Kidney Transplants
King Faisal Specialist Hospital and Research Centre has successfully performed 5,000 kidney transplants since the inception of its Transplant Program in 1981, placing it among a select group of leading global health centres that have achieved this milestone.
July 1, 2024
·
2 min read
LSL Pharma Group Secures $1.5 Million as the First Closing of Its Non-Brokered Private Placement
LSL PHARMA GROUP INC. announced that it has met the closing conditions of a non-brokered private placement for $1,5 million representing the first closing of the private placement financing announced on June 5, 2024.
June 27, 2024
·
5 min read
Press Releases
BriaCell Therapeutics Announces Closing of $5 Million Offering
October 3, 2024
·
3 min read
Schizophrenia
5 Schizophrenia Candidates Chasing BMS’ KarXT
As the FDA prepares to render a verdict on BMS’ closely watched schizophrenia drug,
BioSpace
takes a closer look at the late-stage pipeline for this neuropsychiatric disorder.
September 23, 2024
·
6 min read
·
Heather McKenzie
Press Releases
Nexstim Receives Order for NBS System 5 in Finland
September 27, 2024
·
2 min read
Drug Development
Palatin Announces the Initiation of a Phase 2 Clinical Study of Bremelanotide Co-Administered with a PDE5i for the Treatment of Erectile Dysfunction (ED)
Palatin Technologies, Inc. (NYSE American: PTN) announced the initiation of a Phase 2 clinical study of bremelanotide (BMT), a melanocortin 4 receptor (MC4R), co-administered with a phosphodiesterase 5 inhibitor (PDE5i), for the treatment of erectile dysfunction (ED) in patients that do not respond to PDE5i monotherapy.
June 20, 2024
·
6 min read
1 of 22,596
Next